Pfizer completes community vaccine trials for Prevenar

Pfizer (PFE +0.8%) says it's completed pneumonia case accrual data in a trial of patients over 65 to evaluate whether Prevenar 13 is effective in preventing community-acquired pneumonia cause by 12 pneumococcal strains included in the vaccine.

The trial, which involves about 85,000 people, was needed to fulfil regulatory commitments under the FDA's accelerated approval program.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs